BS01

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Conditions

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Trial Timeline

Jan 8, 2026 → Dec 1, 2031

NCT ID

NCT07158775

About BS01

BS01 is a phase 1/2 stage product being developed by Bionic Sight for Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07158775. Target conditions include Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD).

What happened to similar drugs?

1 of 12 similar drugs in Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) were approved

Approved (1) Terminated (3) Active (8)

🔄avacincaptad pegolAstellas PharmaPhase 3

✅avacincaptad pegolAstellas PharmaApproved

🔄Avacincaptad Pegol + ShamAstellas PharmaPhase 3

❌LampalizumabRochePhase 3

🔄Tinlarebant + PlaceboBelite BioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07158775	Phase 1/2	Recruiting	Jan 8, 2026	Dec 1, 2031	Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
NCT04278131	Phase 1/2	Recruiting	Feb 6, 2020	Dec 30, 2029	Retinitis Pigmentosa

Competing Products

20 competing products in Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

See all competitors

Product	Company	Stage	Hype Score
avacincaptad pegol	Astellas Pharma	Phase 3	40
Avacincaptad Pegol	Astellas Pharma	Phase 2/3	38
avacincaptad pegol	Astellas Pharma	Approved	50
Avacincaptad pegol (ACP)	Astellas Pharma	Pre-clinical	33
Avacincaptad Pegol + Sham	Astellas Pharma	Phase 3	40
ABBV-6628 + SYFOVRE	AbbVie	Phase 1/2	39
FWY003 + Placebo	Novartis	Phase 2	42
CLG561 + LFG316 + Sham injection	Novartis	Phase 2	35
LFG316 + Sham + LFG316 Lower dose	Novartis	Phase 2	35
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
RO7669330 + Syfovre™ + Izervay™	Roche	Phase 1	36
RO7303359	Roche	Phase 1	29
SAR446597 + Sham Comparator	Sanofi	Phase 1/2	39
Pozelimab	Regeneron Pharmaceuticals	Phase 1	36
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)	Ionis Pharmaceuticals	Phase 2	24
Tinlarebant + Placebo	Belite Bio	Phase 3	41
Pegcetacoplan	Apellis Pharmaceuticals	Pre-clinical	24
APL-2 + APL-2	Apellis Pharmaceuticals	Phase 3	34